BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31744339)

  • 1. The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy.
    Ciftciler R; Haznedaroglu IC; Ozcebe O; Aksu S; Sayınalp N; Goker H; Demiroglu H; Buyukasık Y
    Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):17-21. PubMed ID: 31744339
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
    Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
    J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
    Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
    Latagliata R; Petti MC; Fenu S; Mancini M; Spiriti MA; Breccia M; Brunetti GA; Avvisati G; Lo Coco F; Mandelli F
    Blood; 2002 Feb; 99(3):822-4. PubMed ID: 11806982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes in Adult Acute Promyelocytic Leukemia: A Decade Experience.
    Yedla RP; Bala SC; Pydi VR; Kuruva SP; Chennamaneni R; Konatam ML; Paul TR; Gundeti S
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e158-e164. PubMed ID: 31992504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.
    Head D; Kopecky KJ; Weick J; Files JC; Ryan D; Foucar K; Montiel M; Bickers J; Fishleder A; Miller M
    Blood; 1995 Sep; 86(5):1717-28. PubMed ID: 7655004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
    Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
    Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
    Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
    Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid pharmacokinetics and bioavailability in acute promyelocytic leukemia: intracellular concentrations and biologic response relationship.
    Agadir A; Cornic M; Lefebvre P; Gourmel B; Jérôme M; Degos L; Fenaux P; Chomienne C
    J Clin Oncol; 1995 Oct; 13(10):2517-23. PubMed ID: 7595702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survey of outcome in acute promyelocytic leukemia.
    Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
    Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia.
    Çiftçiler R; Haznedaroğlu İC; Sayınalp N; Özcebe O; Aksu S; Demiroğlu H; Göker H; Malkan ÜY; Büyükaşık Y
    Turk J Haematol; 2020 May; 37(2):116-120. PubMed ID: 31475513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond.
    Tallman MS
    Leukemia; 1998 Sep; 12 Suppl 1():S37-40. PubMed ID: 9777894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia.
    Zhang Y; Wu Q; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Jiang Y; Ye J; Jiang X
    BMC Cancer; 2023 Oct; 23(1):1030. PubMed ID: 37875840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to manage acute promyelocytic leukemia.
    Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
    Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.
    Jillella AP; Kota VK
    Blood Rev; 2018 Mar; 32(2):89-95. PubMed ID: 29033137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.